Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis

BACKGROUND: Previous trials demonstrated evidence involving the total effects of gemtuzumab ozogamicin (GO), an anti-CD33 humanized antibody, on treating acute myeloid leukemia (AML). In this updated systematic review, meta-analysis, and network meta-analysis (NMA), we aimed to comprehensively explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qingyu, He, Shujiao, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415423/
https://www.ncbi.nlm.nih.gov/pubmed/34484181
http://dx.doi.org/10.3389/fimmu.2021.683595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415423/
https://www.ncbi.nlm.nih.gov/pubmed/34484181
http://dx.doi.org/10.3389/fimmu.2021.683595

Ejemplares similares